AKUMS
Akums Drugs And Pharmaceuticals Limited
Each stock's 10,000-path forecast, rendered as light.
Akums Drugs And Pharmaceuticals Limited (AKUMS) Stock Analysis & Case Study
Is AKUMS a good buy? The data-driven verdict.
Akums Drugs And Pharmaceuticals Limited (AKUMS) trades at ₹697,on the numbers it tread carefully, a Downstox Snapshot Score of 39/100.
On the numbers, Akums Drugs And Pharmaceuticals Limited (AKUMS) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 36.0× earnings, ROE of 8.4%, a 52% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027-2031.
Last updated . Data snapshot for research, not investment advice.
AKUMS fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
How AKUMS ranks against the 2,373 companies in our screener
- AKUMS's market cap of 10,977 Cr ranks in the 76th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AKUMS's book value of ₹211 ranks in the 73rd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AKUMS's promoter holding of 75.3% ranks in the top 3% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AKUMS's 3-year profit (PAT) growth of 29.0% ranks in the 68th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AKUMS's 3-year revenue growth of 6.0% ranks in the 38th percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AKUMS's debt-to-equity ratio of 0.05x is lower than 86% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
Is AKUMS overvalued? AKUMS P/E vs peers
AKUMS trades at 36.0× earnings. We don't have a verified sector peer group for this stock yet, so no sector peer median or peer comparison table is shown here. Showing one anyway would compare it against an arbitrary set of large-cap names, not real sector peers.
AKUMS share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of AKUMS history (-7%/yr drift, 40%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| AKUMS 2027 | ₹423 | ₹713 | ₹1,203 | +2% |
| AKUMS 2028 | ₹350 | ₹730 | ₹1,519 | +5% |
| AKUMS 2029 | ₹301 | ₹746 | ₹1,848 | +7% |
| AKUMS 2030 | ₹268 | ₹763 | ₹2,173 | +9% |
| AKUMS 2031 | ₹246 | ₹781 | ₹2,482 | +12% |
Median (P50) is the central estimate; the P10-P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability AKUMS goes up, or doubles?
The bull case for AKUMS
- Akums Drugs And Pharmaceuticals Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,848.
The bear case & risks
- AKUMS's P/E of 36.0x is lower than 38% of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- AKUMS's return on equity of 8.4% ranks in the 42nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹301.
AKUMS volatility & expected range, how bumpy is the ride?
Over the last 2.0 years AKUMS compounded at -7%/year with annualized volatility of 40%. That volatility implies a 1-year 80% range of ₹423-₹1,203, the honest backbone behind any single price target.
AKUMS price forecast, the full 60-month probability fan
AKUMS price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds AKUMS hits common targets within the simulated horizon?
Full multi-horizon detail on the AKUMS price target & forecast page.
AKUMS Piotroski F-Score: 6/8, how financially strong is it?
The Piotroski F-Score grades financial strength on profitability, leverage and efficiency checks. Downstox scores the eight checks it can verify from published filings, so 8 is full marks. AKUMS scores 6/8, mixed financial health.
AKUMS MTF margin & leverage across 10 brokers
Margin Trading Facility lets you buy AKUMS with part of the capital. Lower margin % = higher leverage. Rates compared across 10 brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 35.00% | 2.9× |
| Zerodha | 31.40% | 3.2× |
| GrowwCHEAPEST | 31.30% | 3.2× |
| Dhan | 31.40% | 3.2× |
| Kotak Neo | 34.97% | 2.9× |
| Paytm Money | 31.37% | 3.2× |
| Pocketful | 31.47% | 3.2× |
| Anand Rathi | 31.40% | 3.2× |
| Bajaj Broking | 35.00% | 2.9× |
| Share IndiaCHEAPEST | 31.30% | 3.2× |
Compare every broker on the AKUMS MTF page.
About Akums Drugs And Pharmaceuticals Limited: sector, index & market-cap context
Akums Drugs And Pharmaceuticals Limited (AKUMS) is a small-cap NSE-listed company, with a market capitalisation of ₹10,977 Cr. See more stocks on our screener.
How the AKUMS Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Akums Drugs And Pharmaceuticals Limited's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
AKUMS analysis, FAQs
Is Akums Drugs And Pharmaceuticals Limited (AKUMS) a good buy?
On the numbers, Akums Drugs And Pharmaceuticals Limited (AKUMS) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 36.0× earnings, ROE of 8.4%, a 52% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is AKUMS overvalued or undervalued?
AKUMS trades at 36.0× earnings, premium versus the ~22× long-run Nifty average.
What is the AKUMS share price target for 2031?
AKUMS's probability-weighted 2031 median target is ₹781, with an 80% range of ₹246-₹2,482 (10,000-path Monte-Carlo).
What is the probability AKUMS doubles in 5 years?
The modelled probability of AKUMS reaching ₹1,395 (2×) within 5 years is 26%.
What is the bull case for AKUMS?
Akums Drugs And Pharmaceuticals Limited is part of the nifty200 universe with live, tracked fundamentals on Downstox.
What are the risks in AKUMS?
AKUMS's P/E of 36.0x is lower than 38% of the 2,373 NSE companies in our screener, as of 9 Aug 2026. AKUMS's return on equity of 8.4% ranks in the 42nd percentile of the 2,373 NSE companies in our screener, as of 9 Aug 2026.